DSGN

MKT CAP:$776M

Design Therapeutics, Inc.

Market Cap

$776M

Healthcare·Biotechnology·🇺🇸 United States·NASDAQ

Healthcare·Biotechnology·🇺🇸·NASDAQ

Stock Price

$12.96+$3.86 (+42.42%)

Apr 24, 2026

Company Details

Design Therapeutics, Inc. a preclinical-stage biopharmaceutical company, engages in the development of therapies for the treatment of genetic diseases caused by nucleotide repeat expansions. The company's portfolio of products comprises Fri...

CEO

Pratik Shah

IPO Date

Mar 29, 2021

Website

www.designtx.com

Key Metrics TTM

Revenue

$0

— YoY

Net Income

-$70M

EPS (Diluted)

-$1.22

Free Cash Flow

-$55M

Revenue / Share

$0.00

Gross Margin

—

Operating Margin

—

Net Margin

—

FCF Margin

—

P/S

—

P/E

—

Earnings Reports

Q1 2026

May 6, 2026

PENDING

FY 2025

Mar 9, 2026

$0EPS -$1.22

Q4 2025

Mar 9, 2026

$0EPS -$0.27

Q3 2025

Nov 5, 2025

$0EPS -$0.30

Q2 2025

Aug 7, 2025

$0EPS -$0.34

Revenue & Profitability

Quarter	Revenue	Gross Profit	Operating Income
Q1 22	$0	$0	-$13M
Q2 22	$0	$0	-$16M
Q3 22	$0	$0	-$19M
Q4 22	$0	$0	-$19M
Q1 23	$0	$0	-$22M
Q2 23	$0	$0	-$23M
Q3 23	$0	-$137.0K	-$19M
Q4 23	$0	$0	-$15M
Q1 24	$0	-$143.0K	-$14M
Q2 24	$0	-$151.0K	-$15M
Q3 24	$0	$0	-$16M
Q4 24	$0	$0	-$17M
Q1 25	$0	$0	-$20M
Q2 25	$0	-$152.0K	-$22M
Q3 25	$0	-$15M	-$19M
Q4 25	$0	$15M	-$18M

Operating Cash Flow

Quarter	Operating CF	Free CF
Q1 22	-$12M	-$12M
Q2 22	-$11M	-$11M
Q3 22	-$14M	-$14M
Q4 22	-$15M	-$15M
Q1 23	-$17M	-$18M
Q2 23	-$14M	-$14M
Q3 23	-$15M	-$15M
Q4 23	-$13M	-$13M
Q1 24	-$12M	-$13M
Q2 24	-$11M	-$11M
Q3 24	-$10M	-$10M
Q4 24	-$10M	-$10M
Q1 25	-$17M	-$17M
Q2 25	-$14M	-$15M
Q3 25	-$11M	-$11M
Q4 25	-$12M	-$12M

Capital Expenditures

Quarter	CapEx
Q1 22	$76.0K
Q2 22	$244.0K
Q3 22	$310.0K
Q4 22	$288.0K
Q1 23	$87.0K
Q2 23	$89.0K
Q3 23	$53.0K
Q4 23	$27.0K
Q1 24	$195.0K
Q2 24	$161.0K
Q3 24	$16.0K
Q4 24	$0
Q1 25	$72.0K
Q2 25	$87.0K
Q3 25	$0
Q4 25	$34.0K

CapEx

OpEx vs Revenue Growth (YoY)

Quarter	Revenue Growth	OpEx Growth
Q1 22	—	+135.4%
Q2 22	—	+103.4%
Q3 22	—	+69.3%
Q4 22	—	+74.3%
Q1 23	—	+61.9%
Q2 23	—	+44.5%
Q3 23	—	-1.9%
Q4 23	—	-22.0%
Q1 24	—	-33.5%
Q2 24	—	-33.4%
Q3 24	—	-13.7%
Q4 24	—	+10.4%
Q1 25	—	+41.8%
Q2 25	—	+43.4%
Q3 25	—	+18.9%
Q4 25	—	+8.8%

Stock-Based Compensation

Quarter	SBC ($)	% of Revenue
Q1 22	$0	—
Q2 22	$0	—
Q3 22	$0	—
Q4 22	$0	—
Q1 23	$3M	—
Q2 23	$0	—
Q3 23	$3M	—
Q4 23	$3M	—
Q1 24	$3M	—
Q2 24	$3M	—
Q3 24	$3M	—
Q4 24	$3M	—
Q1 25	$4M	—
Q2 25	$4M	—
Q3 25	$4M	—
Q4 25	$3M	—

OpEx Breakdown

Quarter	R&D	G&A	S&M
Q1 22	$9M	$5M	—
Q2 22	$11M	$4M	—
Q3 22	$14M	$5M	—
Q4 22	$14M	$5M	—
Q1 23	$16M	$6M	—
Q2 23	$17M	$6M	—
Q3 23	$13M	$6M	—
Q4 23	$11M	$4M	—
Q1 24	$10M	$5M	—
Q2 24	$10M	$4M	$76.0K
Q3 24	$12M	$4M	—
Q4 24	$12M	$5M	—
Q1 25	$15M	$5M	—
Q2 25	$16M	$6M	—
Q3 25	$15M	$5M	$70.0K
Q4 25	$13M	$5M	—

War Chest

Quarter	Cash	Short-term Investments	Total
Q1 22	$287M	$84M	$371M
Q2 22	$120M	$240M	$359M
Q3 22	$43M	$302M	$344M
Q4 22	$27M	$304M	$330M
Q1 23	$29M	$287M	$315M
Q2 23	$27M	$276M	$303M
Q3 23	$28M	$263M	$291M
Q4 23	$21M	$261M	$282M
Q1 24	$29M	$241M	$271M
Q2 24	$46M	$215M	$261M
Q3 24	$30M	$224M	$254M
Q4 24	$23M	$223M	$245M
Q1 25	$14M	$216M	$230M
Q2 25	$20M	$197M	$216M
Q3 25	$15M	$191M	$206M
Q4 25	$17M	$203M	$220M

Shares Outstanding

Quarter	Shares (Diluted)	QoQ Change	YoY Change
Q1 22	56M	+0.3%	+214.8%
Q2 22	56M	+0.3%	+1.1%
Q3 22	56M	+0.2%	+1.1%
Q4 22	56M	+0.1%	+0.9%
Q1 23	56M	+0.1%	+0.7%
Q2 23	56M	+0.1%	+0.5%
Q3 23	56M	+0.1%	+0.4%
Q4 23	56M	+0.3%	+0.5%
Q1 24	56M	+0.6%	+1.0%
Q2 24	57M	+0.1%	+1.1%
Q3 24	57M	+0.1%	+1.1%
Q4 24	57M	+0.1%	+0.9%
Q1 25	57M	+0.1%	+0.5%
Q2 25	57M	+0.2%	+0.5%
Q3 25	57M	+0.2%	+0.6%
Q4 25	57M	+0.7%	+1.1%

Shares Outstanding

Revenue Per Employee

Period	Revenue/Employee	Employees
Q1 22	$0	38
Q2 22	$0	38
Q3 22	$0	38
Q4 22	$0	58
Q1 23	$0	58
Q2 23	$0	58
Q3 23	$0	58
Q4 23	$0	58
Q1 24	$0	58
Q2 24	$0	58
Q3 24	$0	58
Q4 24	$0	54
Q1 25	$0	54
Q2 25	$0	54
Q3 25	$0	54
Q4 25	$0	5K

Revenue / Employee